Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

INM Insider Trading (InMed Pharmaceuticals)

Insider Ownership Percentage: 4.90%
Insider Buying (Last 12 Months): $69,849.69
Insider Selling (Last 12 Months): $0.00

InMed Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at InMed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

InMed Pharmaceuticals Share Price & Price History

Current Price: $0.47
Price Change: Price Decrease of -0.02 (-4.08%)
As of 06/30/2022 12:43 PM ET

This chart shows the closing price history over time for INM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

InMed Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/13/2022Eric A. AdamsCEOBuy8,560$0.85$7,276.0044,843View SEC Filing Icon  
1/24/2022Bruce S. ColwillCFOBuy5,000$1.09$5,450.00View SEC Filing Icon  
1/6/2022Shane Aaron JohnsonSVPBuy8,500$1.26$10,710.00View SEC Filing Icon  
12/30/2021Shane Aaron JohnsonSVPBuy8,093$1.33$10,763.69View SEC Filing Icon  
11/15/2021Shane Aaron JohnsonSVPBuy5,000$1.37$6,850.00View SEC Filing Icon  
9/28/2021Bruce S. ColwillCFOBuy5,000$1.77$8,850.00View SEC Filing Icon  
9/28/2021Eric A. AdamsCEOBuy11,400$1.75$19,950.00View SEC Filing Icon  
See Full Table
New Investing App Saves Investors an Average of $97,347
Most people are terrible at buying and selling stocks at the right time, but the TradeSmith app takes the emotion out of investing.

Our back test shows, the average investor would've made $97,347 more just by using the TradeSmith app analyzer software.

Check out this FREE video.
>>>

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (NASDAQ:INM)

2.88% of InMed Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

InMed Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/17/2022Empery Asset Management LP61,741$58K0.3%N/A0.437%Search for SEC Filing on Google Icon
8/17/2021Armistice Capital LLC890,000$2.83M0.1%+278.7%9.954%Search for SEC Filing on Google Icon
8/12/2021Penserra Capital Management LLC19,912$49K0.0%N/A0.223%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%Search for SEC Filing on Google Icon
5/17/2021Armistice Capital LLC235,000$0.78M0.0%N/A2.919%Search for SEC Filing on Google Icon
1/29/2021Creative Planning10,990$36K0.0%N/A0.157%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More on InMed Pharmaceuticals

Today's Range

Now: $0.47
Low: $0.47
High: $0.47

50 Day Range

MA: $0.73
Low: $0.49
High: $1.05

52 Week Range

Now: $0.47
Low: $0.42
High: $3.35

Volume

400 shs

Average Volume

152,610 shs

Market Capitalization

$6.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?

InMed Pharmaceuticals' top insider investors include:
  1. Eric A Adams (CEO)
  2. Bruce Colwill (CFO)
  3. Shane Aaron Johnson (SVP)
Learn More about top insider investors at InMed Pharmaceuticals.
Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.

I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).

I grew my $50K into $5.3M
I'll show you how I did it here.